Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
IPRA and PIO significantly improved hepatocellular hypertrophy, micro-vesicular steatosis, lobular inflammation and mild fibrosis in a dose-dependent manner, with the activities of PIO being weaker compared to those of IPRA
First characterized by Sikiric et al
Briggs, G
Cng ngh siu lc y cc phn t cht bo v ng lactose trn qua mng lc, ch gi li protein tinh khit
255,256 Replacing the phosphate backbone by other group improves target affinity, nuclease resistance, and pharmacokinetic properties of nucleic acids
US$ 21.53
US$ 27.65
US$ 22.91
US$ 23.31
